BNT162b2 Protection against the Omicron Variant in Children and Adolescents

doi:10.1056/NEJMoa2202826

. 2022 May 19;386(20):1899-1909.

doi: 10.1056/NEJMoa2202826. Epub 2022 Mar 30.

BNT162b2 Protection against the Omicron Variant in Children and Adolescents

Ashley M Price¹, Samantha M Olson¹, Margaret M Newhams¹, Natasha B Halasa¹, Julie A Boom¹, Leila C Sahni¹, Pia S Pannaraj¹, Katherine Irby¹, Katherine E Bline¹, Aline B Maddux¹, Ryan A Nofziger¹, Melissa A Cameron¹, Tracie C Walker¹, Stephanie P Schwartz¹, Elizabeth H Mack¹, Laura Smallcomb¹, Jennifer E Schuster¹, Charlotte V Hobbs¹, Satoshi Kamidani¹, Keiko M Tarquinio¹, Tamara T Bradford¹, Emily R Levy¹, Kathleen Chiotos¹, Samina S Bhumbra¹, Natalie Z Cvijanovich¹, Sabrina M Heidemann¹, Melissa L Cullimore¹, Shira J Gertz¹, Bria M Coates¹, Mary A Staat¹, Matt S Zinter¹, Michele Kong¹, Brandon M Chatani¹, Janet R Hume¹, Katri V Typpo¹, Mia Maamari¹, Heidi R Flori¹, Mark W Tenforde¹, Laura D Zambrano¹, Angela P Campbell¹, Manish M Patel¹, Adrienne G Randolph¹; Overcoming Covid-19 Investigators

Collaborators, Affiliations

Collaborators

Overcoming Covid-19 Investigators:
Michele Kong, Meghan Murdock, Mary Glas Gaspers, Katri V Typpo, Connor P Kelley, Katherine Irby, Ronald C Sanders, Masson Yates, Chelsea Smith, Melissa A Cameron, Katheryn Crane, Natalie Z Cvijanovich, Geraldina Lionetti, Juliana Murcia-Montoya, Matt S Zinter, Denise Villarreal-Chico, Pia S Pannaraj, Adam L Skura, Daniel Hakimi, Harvey Peralta, Yea Ji Sea, Kennis-Grace Mrotek, Aline B Maddux, Justin M Lockwood, Emily Port, Imogene Carson, Brandon M Chatani, Satoshi Kamidani, Keiko M Tarquinio, Laila Hussaini, Nadine Baida, Kelly N Michelson, Bria M Coates, Simone T Rhodes, Hassan A Khan, Samina S Bhumbra, Courtney M Rowan, Mary Stumpf, Tamara T Bradford, Marla S Johnston, Adrienne G Randolph, Margaret M Newhams, Suden Kucukak, Amber O Orzel, Sabrina R Chen, Benjamin J Boutselis, Timothy P McCadden, Edie Weller, Laura Berbert, Jie He, Sabrina M Heidemann, Heidi R Flori, Patrick Moran, Janet R Hume, Ellen R Bruno, Lexie A Goertzen, Emily R Levy, Supriya Behl, Noelle M Drapeau, Charlotte V Hobbs, Lora Martin, Lacy Malloch, Virginia Austin Harrison, Cameron Sanders, Kayla Patterson, Jennifer E Schuster, Shannon M Hill, Melissa Sullivan, Melissa L Cullimore, Valerie H Rinehart, Lauren A Hoody, Shira J Gertz, Stephanie P Schwartz, Tracie C Walker, Paris C Bennett, Ryan A Nofziger, Nicole A Twinem, Merry L Tomcany, Mary Allen Staat, Chelsea C Rohlfs, Katherine Bline, Amber Wolfe, Kathleen Chiotos, Rebecca L Douglas, Kathlyn Phengchomphet, H Mack, Megan M Bickford, Lauren E Wakefield, Laura Smallcomb, Natasha B Halasa, Laura S Stewart, Meena Golchha, Julie A Boom, Leila C Sahni, Jennifer N Oates, Mia Maamari, Cindy Bowens, Ashley M Price, Samantha M Olson, Manish M Patel, Mark W Tenforde, Laura D Zambrano, Angela P Campbell

Affiliation

¹ From the Covid-19 Response Team, Centers for Disease Control and Prevention (A.M.P., S.M.O., M.W.T., L.D.Z., A.P.C., M.M.P.), the Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine (S.K.), and the Division of Critical Care Medicine, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta (K.M.T.) - all in Atlanta; the Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital (M.M.N., A.G.R.), and the Departments of Anaesthesia and Pediatrics, Harvard Medical School (A.G.R.) - both in Boston; the Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville (N.B.H.); the Department of Pediatrics, Baylor College of Medicine, Immunization Project, Texas Children's Hospital, Houston (J.A.B., L.C.S.), and the Department of Pediatrics, Division of Critical Care Medicine, University of Texas Southwestern, Children's Medical Center, Dallas (M.M.); the Division of Infectious Diseases, Children's Hospital Los Angeles and Departments of Pediatrics and Molecular Microbiology and Immunology, University of Southern California, Los Angeles (P.S.P.), the Division of Pediatric Hospital Medicine, UC San Diego-Rady Children's Hospital, San Diego (M.A.C.), the Division of Critical Care Medicine, UCSF Benioff Children's Hospital, Oakland (N.Z.C.), and the Department of Pediatrics, Divisions of Critical Care Medicine and Allergy, Immunology, and Bone Marrow Transplant, University of California, San Francisco, San Francisco (M.S.Z.) - all in California; Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Children's Hospital, Little Rock (K.I.); the Division of Pediatric Critical Care Medicine, Nationwide Children's Hospital Columbus (K.E.B.), the Division of Critical Care Medicine, Department of Pediatrics, Akron Children's Hospital, Akron (R.A.N.), and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati (M.A.S.) - all in Ohio; the Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora (A.B.M.); the Department of Pediatrics, University of North Carolina at Chapel Hill Children's Hospital, Chapel Hill (T.C.W., S.P.S.); the Division of Pediatric Critical Care Medicine (E.H.M.) and the Department of Pediatrics (L.S.), Medical University of South Carolina, Charleston; the Division of Pediatric Infectious Diseases, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO (J.E.S.); the Departments of Pediatrics and Microbiology, Division of Infectious Diseases, University of Mississippi Medical Center, Jackson (C.V.H.); the Department of Pediatrics, Division of Cardiology, Louisiana State University Health Sciences Center and Children's Hospital of New Orleans, New Orleans (T.T.B.); the Divisions of Pediatric Infectious Diseases and Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester (E.R.L.), and the Division of Pediatric Critical Care, University of Minnesota Masonic Children's Hospital, Minneapolis (J.R.H.) - both in Minnesota; the Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia, Philadelphia (K.C.); the Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis (S.S.B.); the Division of Pediatric Critical Care Medicine, Children's Hospital of Michigan, Central Michigan University, Detroit (S.M.H.), and the Division of Pediatric Critical Care Medicine, Department of Pediatrics, Mott Children's Hospital and University of Michigan, Ann Arbor (H.R.F.); the Division of Pediatric Critical Care, Department of Pediatrics, Children's Hospital and Medical Center, Omaha, NE (M.L.C.); the Division of Pediatric Critical Care, Department of Pediatrics, Cooperman Barnabas Medical Center, Livingston, NJ (S.J.G.); the Division of Critical Care Medicine, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago (B.M. Coates); the Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham (M.K.); the Division of Pediatric Infectious Diseases, Department of Pediatrics, UHealth Holtz Children's Hospital, Miami (B.M. Chatani); and the Department of Pediatrics and Banner Children's at Diamond Children's Medical Center, University of Arizona, Tucson (K.V.T.).

PMID: 35353976
PMCID: PMC9006785
DOI: 10.1056/NEJMoa2202826

BNT162b2 Protection against the Omicron Variant in Children and Adolescents

Ashley M Price et al. N Engl J Med. 2022.

. 2022 May 19;386(20):1899-1909.

doi: 10.1056/NEJMoa2202826. Epub 2022 Mar 30.

Authors

Collaborators

Overcoming Covid-19 Investigators:
Michele Kong, Meghan Murdock, Mary Glas Gaspers, Katri V Typpo, Connor P Kelley, Katherine Irby, Ronald C Sanders, Masson Yates, Chelsea Smith, Melissa A Cameron, Katheryn Crane, Natalie Z Cvijanovich, Geraldina Lionetti, Juliana Murcia-Montoya, Matt S Zinter, Denise Villarreal-Chico, Pia S Pannaraj, Adam L Skura, Daniel Hakimi, Harvey Peralta, Yea Ji Sea, Kennis-Grace Mrotek, Aline B Maddux, Justin M Lockwood, Emily Port, Imogene Carson, Brandon M Chatani, Satoshi Kamidani, Keiko M Tarquinio, Laila Hussaini, Nadine Baida, Kelly N Michelson, Bria M Coates, Simone T Rhodes, Hassan A Khan, Samina S Bhumbra, Courtney M Rowan, Mary Stumpf, Tamara T Bradford, Marla S Johnston, Adrienne G Randolph, Margaret M Newhams, Suden Kucukak, Amber O Orzel, Sabrina R Chen, Benjamin J Boutselis, Timothy P McCadden, Edie Weller, Laura Berbert, Jie He, Sabrina M Heidemann, Heidi R Flori, Patrick Moran, Janet R Hume, Ellen R Bruno, Lexie A Goertzen, Emily R Levy, Supriya Behl, Noelle M Drapeau, Charlotte V Hobbs, Lora Martin, Lacy Malloch, Virginia Austin Harrison, Cameron Sanders, Kayla Patterson, Jennifer E Schuster, Shannon M Hill, Melissa Sullivan, Melissa L Cullimore, Valerie H Rinehart, Lauren A Hoody, Shira J Gertz, Stephanie P Schwartz, Tracie C Walker, Paris C Bennett, Ryan A Nofziger, Nicole A Twinem, Merry L Tomcany, Mary Allen Staat, Chelsea C Rohlfs, Katherine Bline, Amber Wolfe, Kathleen Chiotos, Rebecca L Douglas, Kathlyn Phengchomphet, H Mack, Megan M Bickford, Lauren E Wakefield, Laura Smallcomb, Natasha B Halasa, Laura S Stewart, Meena Golchha, Julie A Boom, Leila C Sahni, Jennifer N Oates, Mia Maamari, Cindy Bowens, Ashley M Price, Samantha M Olson, Manish M Patel, Mark W Tenforde, Laura D Zambrano, Angela P Campbell

Affiliation

¹ From the Covid-19 Response Team, Centers for Disease Control and Prevention (A.M.P., S.M.O., M.W.T., L.D.Z., A.P.C., M.M.P.), the Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine (S.K.), and the Division of Critical Care Medicine, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta (K.M.T.) - all in Atlanta; the Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital (M.M.N., A.G.R.), and the Departments of Anaesthesia and Pediatrics, Harvard Medical School (A.G.R.) - both in Boston; the Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville (N.B.H.); the Department of Pediatrics, Baylor College of Medicine, Immunization Project, Texas Children's Hospital, Houston (J.A.B., L.C.S.), and the Department of Pediatrics, Division of Critical Care Medicine, University of Texas Southwestern, Children's Medical Center, Dallas (M.M.); the Division of Infectious Diseases, Children's Hospital Los Angeles and Departments of Pediatrics and Molecular Microbiology and Immunology, University of Southern California, Los Angeles (P.S.P.), the Division of Pediatric Hospital Medicine, UC San Diego-Rady Children's Hospital, San Diego (M.A.C.), the Division of Critical Care Medicine, UCSF Benioff Children's Hospital, Oakland (N.Z.C.), and the Department of Pediatrics, Divisions of Critical Care Medicine and Allergy, Immunology, and Bone Marrow Transplant, University of California, San Francisco, San Francisco (M.S.Z.) - all in California; Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Children's Hospital, Little Rock (K.I.); the Division of Pediatric Critical Care Medicine, Nationwide Children's Hospital Columbus (K.E.B.), the Division of Critical Care Medicine, Department of Pediatrics, Akron Children's Hospital, Akron (R.A.N.), and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati (M.A.S.) - all in Ohio; the Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora (A.B.M.); the Department of Pediatrics, University of North Carolina at Chapel Hill Children's Hospital, Chapel Hill (T.C.W., S.P.S.); the Division of Pediatric Critical Care Medicine (E.H.M.) and the Department of Pediatrics (L.S.), Medical University of South Carolina, Charleston; the Division of Pediatric Infectious Diseases, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO (J.E.S.); the Departments of Pediatrics and Microbiology, Division of Infectious Diseases, University of Mississippi Medical Center, Jackson (C.V.H.); the Department of Pediatrics, Division of Cardiology, Louisiana State University Health Sciences Center and Children's Hospital of New Orleans, New Orleans (T.T.B.); the Divisions of Pediatric Infectious Diseases and Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester (E.R.L.), and the Division of Pediatric Critical Care, University of Minnesota Masonic Children's Hospital, Minneapolis (J.R.H.) - both in Minnesota; the Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia, Philadelphia (K.C.); the Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis (S.S.B.); the Division of Pediatric Critical Care Medicine, Children's Hospital of Michigan, Central Michigan University, Detroit (S.M.H.), and the Division of Pediatric Critical Care Medicine, Department of Pediatrics, Mott Children's Hospital and University of Michigan, Ann Arbor (H.R.F.); the Division of Pediatric Critical Care, Department of Pediatrics, Children's Hospital and Medical Center, Omaha, NE (M.L.C.); the Division of Pediatric Critical Care, Department of Pediatrics, Cooperman Barnabas Medical Center, Livingston, NJ (S.J.G.); the Division of Critical Care Medicine, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago (B.M. Coates); the Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham (M.K.); the Division of Pediatric Infectious Diseases, Department of Pediatrics, UHealth Holtz Children's Hospital, Miami (B.M. Chatani); and the Department of Pediatrics and Banner Children's at Diamond Children's Medical Center, University of Arizona, Tucson (K.V.T.).

PMID: 35353976
PMCID: PMC9006785
DOI: 10.1056/NEJMoa2202826

Abstract

Background: Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant, which led to increased U.S. hospitalizations for coronavirus disease 2019 (Covid-19), generated concern about immune evasion and the duration of protection from vaccines in children and adolescents.

Methods: Using a case-control, test-negative design, we assessed vaccine effectiveness against laboratory-confirmed Covid-19 leading to hospitalization and against critical Covid-19 (i.e., leading to receipt of life support or to death). From July 1, 2021, to February 17, 2022, we enrolled case patients with Covid-19 and controls without Covid-19 at 31 hospitals in 23 states. We estimated vaccine effectiveness by comparing the odds of antecedent full vaccination (two doses of BNT162b2 messenger RNA vaccine) at least 14 days before illness among case patients and controls, according to time since vaccination for patients 12 to 18 years of age and in periods coinciding with circulation of B.1.617.2 (delta) (July 1, 2021, to December 18, 2021) and omicron (December 19, 2021, to February 17, 2022) among patients 5 to 11 and 12 to 18 years of age.

Results: We enrolled 1185 case patients (1043 [88%] of whom were unvaccinated, 291 [25%] of whom received life support, and 14 of whom died) and 1627 controls. During the delta-predominant period, vaccine effectiveness against hospitalization for Covid-19 among adolescents 12 to 18 years of age was 93% (95% confidence interval [CI], 89 to 95) 2 to 22 weeks after vaccination and was 92% (95% CI, 80 to 97) at 23 to 44 weeks. Among adolescents 12 to 18 years of age (median interval since vaccination, 162 days) during the omicron-predominant period, vaccine effectiveness was 40% (95% CI, 9 to 60) against hospitalization for Covid-19, 79% (95% CI, 51 to 91) against critical Covid-19, and 20% (95% CI, -25 to 49) against noncritical Covid-19. During the omicron period, vaccine effectiveness against hospitalization among children 5 to 11 years of age was 68% (95% CI, 42 to 82; median interval since vaccination, 34 days).

Conclusions: BNT162b2 vaccination reduced the risk of omicron-associated hospitalization by two thirds among children 5 to 11 years of age. Although two doses provided lower protection against omicron-associated hospitalization than against delta-associated hospitalization among adolescents 12 to 18 years of age, vaccination prevented critical illness caused by either variant. (Funded by the Centers for Disease Control and Prevention.).

PubMed Disclaimer

Figures

**Figure 1. Study Enrollment and Outcomes (July 1, 2021–February 17, 2022).**
Covid-19 denotes coronavirus disease 2019.

**Figure 2. Effectiveness of the BNT162b2 Vaccine against Hospitalization for Covid-19, Stratified According to Age and Variant.**
The delta-predominant period was defined as July 1, 2021, through December 18, 2021. The omicron-predominant period was defined as December 19, 2021, to February 17, 2022. For children 5 to 11 years of age, evaluation was limited to the omicron period because of the recent introduction of vaccination in this group (on October 29, 2021). For the subgroup analysis of time since vaccination, 4 case patients were not included because of missing dates of vaccination. Vaccine effectiveness was calculated as (1−adjusted odds ratio)×100, where the odds ratio is the odds of vaccination in case patients as compared with controls.

**Figure 3. Effectiveness of the BNT162b2 Vaccine against Hospitalization for Critical as Compared with Noncritical Covid-19 in Adolescents 12 to 18 Years of Age, Stratified According to Variant.**
Numbers were insufficient to stratify the analysis according to disease severity among children 5 to 11 years of age. In this analysis, only subgroups of case patients were based on disease severity; the entire control group (regardless of disease severity) served as the basis for comparison. Critical Covid-19 was defined as Covid-19 leading to life support (i.e., noninvasive mechanical ventilation [bilevel positive airway pressure or continuous positive airway pressure] or invasive mechanical ventilation, vasoactive infusions, or extracorporeal membrane oxygenation) or death. Information on this outcome was missing for 8 case patients admitted during the omicron period. Vaccine effectiveness was calculated as (1−adjusted odds ratio)×100, where the odds ratio is the odds of vaccination in case patients as compared with controls.

See this image and copyright information in PMC

Comment in

BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
Zeng G. Zeng G. N Engl J Med. 2022 Jun 16;386(24):2345-2346. doi: 10.1056/NEJMc2205107. Epub 2022 May 11. N Engl J Med. 2022. PMID: 35544366 No abstract available.

Cited by

Maternal COVID-19 Vaccine May Reduce the Risk of MIS-C in Infants: A Narrative Review.
Mangat C, Yarrarapu SNS, Singh G, Bansal P. Mangat C, et al. Vaccines (Basel). 2022 Sep 2;10(9):1454. doi: 10.3390/vaccines10091454. Vaccines (Basel). 2022. PMID: 36146531 Free PMC article. Review.
The mechanisms of immune response and evasion by the main SARS-CoV-2 variants.
Chen Q, Zhang J, Wang P, Zhang Z. Chen Q, et al. iScience. 2022 Oct 21;25(10):105044. doi: 10.1016/j.isci.2022.105044. Epub 2022 Sep 2. iScience. 2022. PMID: 36068846 Free PMC article. Review.
Safety, Efficacy, and Immunogenicity of Varying Types of COVID-19 Vaccines in Children Younger Than 18 Years: An Update of Systematic Review and Meta-Analysis.
Tian Y, Chen L, Shi Y. Tian Y, et al. Vaccines (Basel). 2022 Dec 30;11(1):87. doi: 10.3390/vaccines11010087. Vaccines (Basel). 2022. PMID: 36679932 Free PMC article. Review.
Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States.
Wells CR, Pandey A, Moghadas SM, Fitzpatrick MC, Singer BH, Galvani AP. Wells CR, et al. Ann Intern Med. 2024 May;177(5):609-617. doi: 10.7326/M23-2451. Epub 2024 Mar 26. Ann Intern Med. 2024. PMID: 38527289 Free PMC article.
PaedVacCOVID - safety of the BNT162b2 vaccine against the SARS-CoV-2 in children with and without comorbidities aged 5 to 11 years.
Holzwarth S, Saadat K, Jorczyk M, Dreßen S, Kotsias-Konopelska S, Schlegtendal A, Maier C, Schmitt J, Paul K, Pagel J, Muntau AC, Berner R, Brinkmann F, Toepfner N. Holzwarth S, et al. Infection. 2025 Apr;53(2):615-624. doi: 10.1007/s15010-024-02427-2. Epub 2024 Nov 11. Infection. 2025. PMID: 39527343 Free PMC article.

See all "Cited by" articles

References

1. Food and Drug Administration. FDA approves first COVID-19 vaccine. August 23, 2021. (https://www.fda.gov/news-events/press-announcements/fda-approves-first-c...).
1. Food and Drug Administration. FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age. October 29, 2021. (https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfize...).
1. Glatman-Freedman A, Hershkovitz Y, Kaufman Z, Dichtiar R, Keinan-Boker L, Bromberg M. Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 delta variant infection, Israel, 2021. Emerg Infect Dis 2021;27:2919-2922. - PMC - PubMed
1. Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents. N Engl J Med 2022;386:713-723. - PMC - PubMed
1. Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of Pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12–18 years — United States, June–September 2021. MMWR Morb Mortal Wkly Rep 2021;70:1483-1488. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Supplementary concepts

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Food and Drug Administration. FDA approves first COVID-19 vaccine. August 23, 2021. (https://www.fda.gov/news-events/press-announcements/fda-approves-first-c...).

[2] Food and Drug Administration. FDA approves first COVID-19 vaccine. August 23, 2021. (https://www.fda.gov/news-events/press-announcements/fda-approves-first-c...).

[3] Food and Drug Administration. FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age. October 29, 2021. (https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfize...).

[4] Food and Drug Administration. FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age. October 29, 2021. (https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfize...).

[5] Glatman-Freedman A, Hershkovitz Y, Kaufman Z, Dichtiar R, Keinan-Boker L, Bromberg M. Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 delta variant infection, Israel, 2021. Emerg Infect Dis 2021;27:2919-2922. - PMC - PubMed

[6] Glatman-Freedman A, Hershkovitz Y, Kaufman Z, Dichtiar R, Keinan-Boker L, Bromberg M. Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 delta variant infection, Israel, 2021. Emerg Infect Dis 2021;27:2919-2922. - PMC - PubMed

[7] Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents. N Engl J Med 2022;386:713-723. - PMC - PubMed

[8] Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents. N Engl J Med 2022;386:713-723. - PMC - PubMed

[9] Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of Pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12–18 years — United States, June–September 2021. MMWR Morb Mortal Wkly Rep 2021;70:1483-1488. - PMC - PubMed

[10] Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of Pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12–18 years — United States, June–September 2021. MMWR Morb Mortal Wkly Rep 2021;70:1483-1488. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

BNT162b2 Protection against the Omicron Variant in Children and Adolescents

Collaborators

Affiliation

BNT162b2 Protection against the Omicron Variant in Children and Adolescents

Authors

Collaborators

Affiliation

Abstract

Figures

Comment in

Similar articles

Cited by

References

MeSH terms

Substances

Supplementary concepts

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Abstract

Figures

Comment in

Similar articles

Cited by

References

MeSH terms

Substances

Supplementary concepts

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous